Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
The small tyrosine kinase (TK) inhibitor imatinib mesylate (Gleevec, STI571) protects against both type 1 and type 2 diabetes, but as it inhibits many TKs and other proteins, it is not clear by which mechanisms it acts. This present review will focus on the possibility that imatinib acts, at least i...
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Upsala Medical Society
2022-09-01
|
| Sarja: | Upsala Journal of Medical Sciences |
| Aiheet: | |
| Linkit: | https://ujms.net/index.php/ujms/article/view/8841/14851 |